Find Your Broker
Share Name Share Symbol Market Type Share ISIN Share Description
Midatech Pharma LSE:MTPH London Ordinary Share GB00BRTL9B63 ORD 0.005P
  Price Change % Change Share Price Shares Traded Last Trade
  +0.00p +0.00% 9.25p 4,064 08:00:00
Bid Price Offer Price High Price Low Price Open Price
9.00p 9.50p 9.25p 9.25p 9.25p
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 6.76 -17.33 -31.00 5.7

Midatech Pharma (MTPH) Latest News

More Midatech Pharma News
Midatech Pharma Takeover Rumours

Midatech Pharma (MTPH) Share Charts

1 Year Midatech Pharma Chart

1 Year Midatech Pharma Chart

1 Month Midatech Pharma Chart

1 Month Midatech Pharma Chart

Intraday Midatech Pharma Chart

Intraday Midatech Pharma Chart

Midatech Pharma (MTPH) Discussions and Chat

Midatech Pharma Forums and Chat

Date Time Title Posts
01/12/201812:20Midatech Pharma (MTPH) sees 10-fold increase211
23/7/201811:43Midatech Pharma (MTPH) One to Watch -
03/1/201712:41Midatech Pharma PLC181
10/8/201607:55MTPH-

Add a New Thread

Midatech Pharma (MTPH) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
13:25:599.0080872.72O
10:17:319.002,791251.19O
09:55:169.1046542.32O
View all Midatech Pharma trades in real-time

Midatech Pharma (MTPH) Top Chat Posts

DateSubject
10/12/2018
08:20
Midatech Pharma Daily Update: Midatech Pharma is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker MTPH. The last closing price for Midatech Pharma was 9.25p.
Midatech Pharma has a 4 week average price of 9p and a 12 week average price of 9p.
The 1 year high share price is 53p while the 1 year low share price is currently 9p.
There are currently 61,184,135 shares in issue and the average daily traded volume is 147,454 shares. The market capitalisation of Midatech Pharma is £5,659,532.49.
01/9/2018
03:55
jamtomorrow2: You said it. It’s not bioequivalent - but it is potentially better. The problem is that you will have to prove that to the FDA in a large Phase 3 trial. That’s going to cost time and big money, which Midatech doesn’t have. It will therefore need to partner the product and take upfronts and royalties as opposed to keeping 100% control of the product and selling it through Dara. The mathematics of all this are far from straightforward hence the modest share price reaction.
22/2/2018
06:58
jamtomorrow2: Another new low. Those peak sales forecasts for both MTD201 and the brain cancer drug look pure fantasy to me. Sandostatin is not patent protected anymore and it looks like three generics will be on the market before MTD201 is launched in 2020. The price by that time will be way lower than now - something that the forecasts haven’t taken into account. Also the brain cancer drug has such a limited market that I have no idea how they have arrived at their figures. Bearing in mind that DARA seems to be incapable of marketing its existing drugs it’s very hard to fathom how they will be capable of selling 10-15 times the current sales level. Also what happens to the recently negotiated loan if MTD201 fails to achieve bioequivalence? We haven’t been told the terms and conditions attached to the loan but one would assume that it would be subject to meeting certain drug development goals and surely MTD201 bioequivalence is one of those goals. Would the loan then have to be repaid quickly leaving MTPH in desperate need of new cash just as the share price crashes further? Continous delays and a plethora of unanswered questions surround this company.
16/1/2018
23:04
jamtomorrow2: The share price is 45p for a reason. One failed trial, a loss making acquisition and two approvals to conduct a trial after 3 years as a public company. That’s all folks. But at least one shareholder seems happy.
09/1/2018
23:02
jamtomorrow2: MTD201 study approved!! Somewhat misleading headline! I was under the impression that it had been approved to commence ages ago. Nobody ever said the hold-up was due to not having EU approval. So the previously quoted reason for the hold-up of problems relating to gearing up to production levels at the Spanish lab was basically as misleading as the heading to today’s announcement. So when is this wretched trial actually going to start? It’s delay after delay after delay. No wonder the share price is so bombed out. Also why do we hear nothing about the success or otherwise of the compansionate UK program re childrens brain cancer? This had been going on for a couple of years now. If successful you’d have thought they’d be singing out the good news from the rooftops.
05/4/2017
12:57
jamtomorrow2: Loss of £20m and one failed drug and a share price down 50%. A really great year!
26/4/2016
11:47
thomasthetank1: Read Panmure Gordon & Co's note on MIDATECH PHARMA, out this morning, by visiting hxxps://www.research-tree.com/company/GB00BRTL9B63 "More good news this morning. Positive pharmacokinetic data from Midatech’s Q-Octreotide programme (MTD201) for the treatment of acromegaly and carcinoid syndrome demonstrate a favourable profile against the reference and market leader Sandostatin LAR Depot (Novartis). This paves the way towards IND submission and bio-equivalence in human studies expected in late 2016 and today’s news adds further weight and momentum to the company’s recent news flow. With significant headroom on the current share price ..."
13/4/2016
11:33
thomasthetank1: Read Panmure's note on Midatech Pharma (MTPH), out this morning, by visiting www.research-tree.com … “Today’s FY15 results see revenues of £1.38m ahead of our expectations (PGe £1.30m, 2014: £0.16m) and, adjusting for one-off listing/acquisition items, the strong performance is also reflected at the bottom-line, with adjusted pre-tax loss of £9.9m vs PGe £10.6m loss. Delivery of this kind, during a period of high activity, reflects well on management capabilities and bandwidth. The parallel strands of commercial and pipeline development bode well for the long-term risk and growth profile of the business and we note strong revenues from marketed products in the first three months of 2016 with trading ‘slightly ahead of market expectations’. We retain our earnings forecasts unchanged for now but will look to future updates with respect to potential headroom on our forecasts. In the meantime, our view remains that there is significant headroom on the current share price…”
13/3/2016
19:47
hutch_pod: Good interview. Liked hearing his view on the share price and Dara shareholder profit taking. Hope April delivers good progress.
30/12/2015
09:57
hutch_pod: Did you see this from 17th? hTtp://seekingalpha.com/author/bart-van-velzen/comments High time for an update on this article: the merger has been approved, the ADR's have been issued, but the idea so far hasn't worked out like I had planned. One of the risks highlighted in the article was: "Midatech's ADRs trading in tandem with its Ordinary Shares could cause the price of the ADRs to go up, but the same mechanism could obviously also cause the price of the Ordinary Shares in the UK to go down." Unfortunately, this is what happened. Since the deal was completed the MTPH share price in London took a bath and has now dropped close to 25% in about two weeks, making this deal a nightmare for the UK holders. I indicated in the article MTPH was illiquid and unshortable; I knew the shares in London would likely drop as a result of ADR-holders converting and selling, explaining some of the premium to the US price. But I hadn't expected an <20M take over to cause MTPH to shed >30M in market cap which in itself is of course fundamentally questionable; Midatech + DARA combined is now worth less than Midatech itself used to do. Also, trading volumes were horrendously low. I had expected MTPH-management, or any of its many experienced institutional investors, to see this coming based on the illiquidity of MTPH-shares, and to have at least something of contingency plan ready. Apparently so far they didn't. One would assume experienced investors like Neil Woodford (who holds an 18% stake through Woodford Investment Management) would not allow his fund to lose millions in a few days on trading volumes of about 40K $ without stepping in. One would also assume he, or any one of the other holders being hung out to dry, still will. It wouldn't take much. Anyway, with regards to ADR conversion: no US listed ADR I'm aware of trades at a discount to its UK listed peers, and MTP won't either in the mid term
18/12/2015
15:56
njw2: The problem is quite simple, there is a major seller in the US line ( probably someone being stopped out from the total bulls up with the confusion on the merger )and until this is dealt with the share price collapse will continue. Maybe if someone at the company had a brain they would find the seller and take him out. Until that happens the share price will continue to collapse and there is no bottom on this.
Midatech Pharma share price data is direct from the London Stock Exchange
Your Recent History
LSE
MTPH
Midatech P..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20181210 19:18:22